6:44 PM
 | 
Feb 01, 2007
 |  BC Extra  |  Company News

AstraZeneca unveils R&D plans

AstraZeneca (LSE:AZN; AZN) announced on its earnings call on Thursday the areas in which it will be focusing its R&D development. The company said it will build in the areas of analgesia, diabetes/obesity, infection, inhalation, and translational science oncology. In addition, the company will maintain its focus on Alzheimer's...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >